RxSight, Inc.

RxSight, Inc. (RXST) priced its initial public offering on Jul 30, 2021 at $16.00 per share, within its $16.00–$18.00 range, raising $117.6M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $424.3M. J.P. Morgan was lead-left underwriter, joined by BofA Securities, Leerink Partners and Wells Fargo and others. Wilson Sonsini advised the company and Davis Polk advised the underwriters.

RxSight, Inc. is a commercial-stage medical technology company focused on vision after cataract surgery. Its Light Adjustable Lens system lets doctors customize and optimize visual acuity after surgery using ultraviolet light from a delivery device.

Status

IPO

Ticker

RXST

Exchange

Nasdaq Global Market

Priced

Jul 30, 2021

IPO price

$16.00

Price range

$16.00–$18.00

Raised

$117.6M

Market cap at IPO price

$424.3M

First filed

Jul 9, 2021

Underwriters

J.P. Morgan, BofA Securities, Leerink Partners, Wells Fargo and BTIG

Company counsel

Wilson Sonsini

Underwriters' counsel

Davis Polk

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.